Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 14/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.54 |
| ▸ | LCK | P06239 | 8/20 | 0.52 |
| ▸ | FYN | P06241 | 8/20 | 0.52 |
| ▸ | YES1 | P07947 | 8/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045771 | 1.00 | MET (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL29394654 | 1.00 | MET (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL31016301 | 1.00 | MET (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL5407995 | 0.88 | MET (0.79) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL5412097 | 0.82 | MET (0.70) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL29689641 | 0.82 | SRC (0.74) | METKDRFGFR1SRCPDGFRB | |
| SCHEMBL31678823 | 0.78 | KDR (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL29394393 | 0.78 | KDR (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL31016300 | 0.78 | KDR (1.00) | METKDRFGFR1MEN1CCNE1 | |
| SCHEMBL93713 | 0.78 | KDR (1.00) | METKDRFGFR1MEN1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140348819-A1 | Methods of Treating Cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-8729043-B2 | Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH S.A. (CH) | 2014-05-20 | — | — | US | claimed |
| US-8388958-B2 | Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH SA (CH) | 2013-03-05 | — | — | US | claimed |
| WO-2012178038-A1 | METHODS OF TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2012-12-27 | — | — | WO | claimed |
| US-20120134996-A1 | Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH SA, (CH) | 2012-05-31 | — | — | US | claimed |
| EP-1981981-B1 | ANTI-MET MONOCLONAL ANTIBODY, FRAGMENTS AND VECTORS THEREOF, FOR THE TREATMENT OF TUMORS AND CORRESPONDING PRODUCTS | METHERESIS TRANSLATIONAL RES SA (CH) | 2011-06-29 | — | — | EP | claimed |
| US-20090285807-A1 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products | Pierre Fabre Médicament (FR) | 2009-11-19 | — | — | US | claimed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | claimed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | claimed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-8729043-B2 | Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH S.A. (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8388958-B2 | Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH SA (CH) | 2013-03-05 | — | — | US | disclosed |
| US-20120134996-A1 | Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH SA, (CH) | 2012-05-31 | — | — | US | disclosed |
| US-20090285807-A1 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products | Pierre Fabre Médicament (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | MET 1078/4885KDR 3515/4885FGFR1 2064/4885 |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | MET 2590/4885KDR 1657/4885FGFR1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.